| --- | --- | --- | --- | --- | |-------|-------|-------------------------------|-------|-------| | | | | | | | | | | | | | | | Second Quarter 2021 Financial | | | | | | Results and Recent Corporate | | | | | | and Pipeline Activity | | | AUGUST 3, 2021 Agenda | --- | --- | |---------------------------------------------------------------------------------|-------| | Introduction \| Sanj K. Patel, CEO and Chairman of the Board | | | ARCALYST® Launch Quarter \| Ross Moat, Head of ARCALYST Franchise | | | Port ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38492 Kiniksa Pharmaceuticals, Ltd. (Exact Name of Registrant as Specified in Its Charter) Bermuda 98-1327726 ...

Financial Data and Key Metrics Changes - Net revenue for ARCALYST in Q2 2021 was $7.7 million, marking the first quarter of sales for the product [8][43] - The net loss for Q2 2021 was $41.6 million, compared to $37.5 million for the same period last year [46] - Cash reserves at the end of Q2 2021 were approximately $226 million, expected to fund operations into 2023 [46][51] Business Line Data and Key Metrics Changes - Revenue sources for ARCALYST were evenly split between recurrent pericarditis, legacy CAPS, and DIRA indications, with a strong start in recurrent pericarditis [15][43] - The company expects Q3 2021 ARCALYST revenue to be between $9 million and $10 million, driven primarily by recurrent pericarditis demand [19][44] Market Data and Key Metrics Changes - Approximately 35% of recurrent pericarditis prescriptions came from clinical trial sites, while 65% were from broader practices [20][21] - Over 100 physicians who did not participate in the RHAPSODY trial prescribed ARCALYST, indicating a promising breadth of prescribing base [22] Company Strategy and Development Direction - The company is focused on maximizing value across its portfolio, with a strong emphasis on the commercial launch of ARCALYST and ongoing clinical trials for Mavrilimumab, Vixarelimab, and KPL-404 [10][49] - Kiniksa aims to establish a strong presence in recurrent pericarditis treatment, leveraging positive feedback from physicians and patients [50] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the initial launch progress of ARCALYST and the potential for continued growth in the coming quarters [7][9] - The company is well-positioned for long-term growth with its pipeline assets and expects to execute effectively throughout the year [11][51] Other Important Information - The company has seen a greater than 90% approval rate for payer decisions regarding ARCALYST, facilitating patient access [24] - The Kiniksa OneConnect patient support program is crucial for optimizing the patient experience with ARCALYST [30] Q&A Session Summary Question: What is the mix of physicians prescribing ARCALYST? - The prescribing physicians are from a mix of academic and community settings, with a broad prescriber base emerging since the launch [56] Question: How does the set of 100 physicians compare to initial targeted accounts? - Many of the 100 prescribers come from the targeted accounts, with efforts made to increase awareness through digital marketing and webinars [59] Question: Has the delta variant impacted enrollment in the Phase 3 study for COVID-related ARDS? - The Phase 3 trial continues on pace, with over 75% enrollment despite the delta variant's impact on global COVID-19 cases [62] Question: What is the disposition of patients who received prescriptions this quarter? - The patient base includes both long-term recurrent pericarditis patients transitioning from other treatments and new patients starting ARCALYST [66] Question: What is the timeline for data from the prurigo nodularis study? - No specific timelines for data presentation from the Vixarelimab Phase 2b study have been disclosed, but the study is designed to provide important dose-ranging information [68] Question: How does the launch trajectory compare to expectations? - The company is pleased with the launch results, with a strong team in place and a positive trajectory expected moving forward [71]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38492 Kiniksa Pharmaceuticals, Ltd. (Exact Name of Registrant as Specified in Its Charter) Bermuda 98-1327726 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38492 Kiniksa Pharmaceuticals, Ltd. (Exact name of registrant as specified in its charter) (State or other jurisdi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38492 Kiniksa Pharmaceuticals, Ltd. (Exact Name of Registrant as Specified in Its Charter) (State or Othe ...

Every Second Counts!™ Corporate Presentation September 2020 Forward Looking Statements This presentation (together with any other statements or information that we may make in connection herewith) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to Kiniksa Pharmaceuticals, Ltd. (and its consolidated subsidiaries, collectively, unless context otherwise requires, "Kiniksa," "we," "us" or "our"). In some cases, you can identify forward ...

Every Second Counts!™ Corporate Presentation August 2020 Forward Looking Statements This presentation (together with any other statements or information that we may make in connection herewith) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to Kiniksa Pharmaceuticals, Ltd. (and its consolidated subsidiaries, collectively, unless context otherwise requires, "Kiniksa," "we," "us" or "our"). In some cases, you can identify forward loo ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38492 Kiniksa Pharmaceuticals, Ltd. (Exact Name of Registrant as Specified in Its Charter) Bermuda 98-1327726 ...

FORM 10-Q (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38492 Kiniksa Pharmaceuticals, Ltd. (Exact Name of Registrant as Specified in Its Charter) Bermuda 98-1327726 ...